A “battle” between the UK government and the pharmaceutical industry over drug prices has forced the government to delay publication of its plan for the life sciences, according to The Financial Times. The release of the life sciences review, initially scheduled for the start of this week, was delayed in large part because both sides […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!